Category Archives: Biotech & Pharma

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) plunged into the close of 2016, and hasn’t been able to stage any degree of recovery throughout early 2017. The company fell foul of some negative data surrounding its lead asset in December,...

Opexa Therapeutics Inc (NASDAQ:OPXA) ran up towards the end of last week on a spike in volume, despite a lack of any clear catalysts. The company has been something of a dead entity for the last couple of months, having put out data from its...

The last time we talked about CV Sciences Inc (OTCMKTS:CVSI) was back in October. Shares then went on to an epic run and hit highs just under $1 ahead of the November marijuana ballot initiatives. We’re liking the price action again in...

Proto Script Pharmaceutical Corp (OTCMKTS:PSCR) has risen from $0.32 a share at the start of December to $1.62 a share at last close, a more than 400% gain across the period.  There is a promotional campaign running in the background right...

It has been a big week for low float runners in the biotech space, and things don’t look like they’re going to slow down as the week draws to a close. Another example of this sort of action has just popped up, in the form of MYOS...

We’re always on the lookout for biotech runners, and one that’s impossible to overlook right now is Transgenomic Inc (NASDAQ:TBIO). The company gained close to 300% on Thursday, and looks set to continue its run into the end of...

Dextera Surgical Inc (NASDAQ:DXTR) is up more than 120% so far this week, on a corporate update put out by management to address the fiscal 2017 sales of its lead asset. If the numbers outlined in the update can be hit, and based on the numbers...

When Rennova Health Inc (NASDAQ:RNVA) announced mid December that it was pricing a public offering, the company took a considerable hit. Throughout the latter half of the month, and into early 2017, this decline continued. Late this week, however,...

Genocea Biosciences Inc (NASDAQ:GNCA) found itself on the wrong side of an Adam Feuerstein Tweet back in March, 2016, when the latter highlighted an interim release as being baseless from an efficacy perspective, rooted in the fact that the...

Blake Therapeutics Inc (OTCMKTS:BKIT) is a new promo on the OTC Markets that is capturing investor attention. The promo was kicked off this week at $.91 a share on a surge in volume. There looks to be big money behind BKIT and this creates...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter